Tumor DNA sequencing has expanded opportunities for precision oncology, but molecular profiling alone does not always explain treatment resistance or predict therapeutic response. Combining patient-derived three-dimensional (3D) cancer models with functional drug screening and multiomics analyses offers a complementary approach for investigating tumor biology and evaluating potential treatment strategies in clinically relevant timeframes.
This poster presentation discusses an integrated workflow that combines 3D bioprinted colorectal cancer tumoroids, RNA sequencing, proteomics, and drug response profiling to preserve subtype-specific biology, investigate resistance mechanisms, and identify alternative therapeutic approaches for patient-specific research.
Watch this poster presentation to learn:
- How 3D tumoroid models preserve subtype-specific tumor biology
- How RNA sequencing and proteomics reveal potential resistance mechanisms
- How integrated drug screening informs alternative therapeutic hypotheses
